Global multi-stakeholder endorsement of the MAFLD definition N Méndez-Sánchez, E Bugianesi, RG Gish, F Lammert, H Tilg, ... The lancet Gastroenterology & hepatology 7 (5), 388-390, 2022 | 179 | 2022 |
Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease Y Yilmaz, E Ulukaya, OO Gul, M Arabul, CB Gul, O Atug, AY Oral, S Aker, ... Clinical biochemistry 42 (9), 802-807, 2009 | 74 | 2009 |
Evaluation of chromosome aberrations, sister chromatid exchange and micronuclei in patients with type-1 diabetes mellitus N Cinkilic, S Kiyici, S Celikler, O Vatan, OO Gul, E Tuncel, R Bilaloglu Mutation Research/Genetic Toxicology and Environmental Mutagenesis 676 (1-2 …, 2009 | 58 | 2009 |
Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center M Calapkulu, S Cander, OO Gul, C Ersoy Diabetes & Metabolic Syndrome: Clinical Research & Reviews 13 (2), 1031-1034, 2019 | 54 | 2019 |
Turkish nationwide survEy of glycemic and other Metabolic parameters of patients with Diabetes mellitus (TEMD study) A Sonmez, C Haymana, F Bayram, S Salman, OS Dizdar, E Gurkan, ... Diabetes research and clinical practice 146, 138-147, 2018 | 47 | 2018 |
Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients S Kiyici, C Ersoy, A Kaderli, M Fazlioglu, F Budak, C Duran, OO Gul, ... diabetes research and clinical practice 86 (1), 44-50, 2009 | 42 | 2009 |
Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients OO Gul, E Tuncel, Y Yilmaz, E Ulukaya, CB Gul, S Kiyici, AY Oral, M Guclu, ... Metabolism 59 (1), 64-69, 2010 | 38 | 2010 |
A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry) M Kayikcioglu, L Tokgozoglu, M Yilmaz, L Kaynar, M Aktan, RB Durmuş, ... Atherosclerosis 270, 42-48, 2018 | 34 | 2018 |
Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: results of … M Kayikcioglu, O Kuman-Tunçel, S Pirildar, M Yílmaz, L Kaynar, M Aktan, ... Journal of clinical lipidology 13 (3), 455-467, 2019 | 33 | 2019 |
Evaluation of insulin resistance and plasma levels for visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome OO Gul, S Cander, B Gul, E Açıkgoz, E Sarandol, C Ersoy European cytokine network 26, 73-78, 2015 | 30 | 2015 |
Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: a cross-sectional … OO Gul, N Cinkilic, CB Gul, S Cander, O Vatan, C Ersoy, D Yılmaz, ... Mutation Research/Genetic Toxicology and Environmental Mutagenesis 757 (1 …, 2013 | 26 | 2013 |
Effect of levothyroxine treatment on clinical symptoms and serum cytokine levels in euthyroid patients with chronic idiopathic urticaria and thyroid autoimmunity S Kiyici, OO Gul, EB Baskan, S Hacioglu, F Budak, E Erturk, S Imamoglu Clinical and experimental dermatology 35 (6), 603-607, 2010 | 26 | 2010 |
How the COVID-19 outbreak affected patients with diabetes mellitus? P Sisman, I Polat, E Aydemir, R Karsi, OO Gul, S Cander, C Ersoy, ... International Journal of Diabetes in Developing Countries, 1-9, 2021 | 25 | 2021 |
What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)? M Kayikcioglu, L Tokgozoglu, V Dogan, C Ceyhan, A Tuncez, M Kutlu, ... Atherosclerosis 277, 341-346, 2018 | 22 | 2018 |
Relationship between glycemic control, microalbuminuria and cognitive functions in elderly type 2 diabetic patients CB Gul, O Oz Gul, S Cander, A Eroglu, M Hartavi, N Keni, A Bayindir, ... Renal Failure 36 (8), 1258-1262, 2014 | 17 | 2014 |
Prevalence and correlates of erectile dysfunction in type 2 diabetes mellitus: a cross-sectional single-center study among Turkish patients S Cander, S Coban, S Altuner, O Oz Gul, ZA Yetgin, A Akkurt, H Ucar, ... Metabolic syndrome and related disorders 12 (6), 324-329, 2014 | 17 | 2014 |
Retrospective analysis of vitamin D status on ınflammatory markers and course of the disease in patients with COVID-19 infection YA Ünsal, ÖÖ Gül, S Cander, C Ersoy, E Aydemir, C Ateş, Z Uzun, ... Journal of Endocrinological Investigation, 1-7, 2021 | 16 | 2021 |
The prevalence of obesity and related factors: An urban survey study AG Salici, P Sisman, OO Gul, T Karayel, S Cander, C Ersoy Endocrine Abstracts 49, 2017 | 15 | 2017 |
Does metabolic syndrome increase erectile dysfunction and lower urinary tract symptoms? S Coban, S Cander, MS Altuner, I Keles, OO Gul Urology Journal 11 (4), 1820-1824, 2014 | 15 | 2014 |
Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy S Kiyici, C Ersoy, OO Gul, E Sarandol, M Demirci, E Tuncel, D Sigirli, ... Experimental and clinical endocrinology & diabetes 117 (08), 386-390, 2009 | 14 | 2009 |